Clinicaltrials.gov identifier:
NCT02032823
Study Contact Information:
- Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)
About the Study
The OlympiA trial is the first major study to test the olaparib (Lynparza) for people with mutation-associated breast cancer in the setting (after surgery) for people with earlier-stage ( 2 or 3) cancers. OlympiA is a phase III clinical trial looking at the safety and effectiveness of for women with 2 or 3 breast cancer with a mutation after they have completed standard therapy.
The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium.
The study is no longer enrolling patients.
The study is no longer enrolling patients.